Altimmune (ALT) Cash from Financing Activities (2010 - 2026)

Altimmune (ALT) has reported Cash from Financing Activities for 17 consecutive years, with $78.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 130.0% year-over-year to $78.5 million; the TTM figure through Mar 2026 stood at $251.2 million (up 465.45% YoY), while the FY2025 annual figure was $206.8 million, up 1959.36% from the prior year.
• Cash from Financing Activities slipped to $78.5 million in Q1 2026 per ALT's latest filing, from $81.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $81.1 million in Q4 2025 and bottomed at -$302000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $25.8 million across 5 years, with a median of $13.1 million in 2023.
• On a YoY basis, Cash from Financing Activities climbed as much as 169295.35% in 2023 and fell as far as 109.49% in 2023.
• Altimmune's Cash from Financing Activities stood at -$43000.0 in 2022, then soared by 169295.35% to $72.8 million in 2023, then sank by 86.14% to $10.1 million in 2024, then surged by 704.46% to $81.1 million in 2025, then declined by 3.27% to $78.5 million in 2026.
• Business Quant data shows ALT's Cash from Financing Activities at $78.5 million in Q1 2026, $81.1 million in Q4 2025, and $39.3 million in Q3 2025.